Watch More Highlights

Erin Grannan, PharmD, BCOP, of The University of Texas MD Anderson Cancer Center, discusses the latest updates from the SUMMIT trial that advanced practitioners need to be aware of. Researchers explored the promising combinations of neratinib plus fulvestrant plus trastuzumab, neratinib plus trastuzumab, as well as fulvestrant alone. The combination regimens appeared to benefit patients with hormone–receptor positive HER2-mutated metastatic breast cancer who have had prior exposure to CDK4/6 inhibitors, and those with HER2-mutated triple-negative disease (Abstract GS4-10).

Copyright © 2010-2021 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.